The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat

Osteoporosis International

Volumn 6, Issue 2, 1996, Pages 166-170

  Fleisch, H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bisphosphonates; Bone resorption; Calcium balance; Calcium metabolism; Ibandronate; Rat

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM 45; IBANDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM ABSORPTION; CALCIUM BALANCE; CALCIUM METABOLISM; FEMALE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE RESORPTION; CALCIUM; CALCIUM RADIOISOTOPES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; KINETICS; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ATOMIC;

EID: 0029970562     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623942     Document Type: Article

References (20)

1. Kanis JA. Drugs used for the treatment of Paget's disease. In: Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1991:159-216.
2. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 2nd ed. The Parthenon Publishing Group, New York, London, 1995.
3. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH III. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
4. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimoni P. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469-71.
5. Valkema R, Vismans FJE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989;5:183-92.
6. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994;4:76-83.
7. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RL, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC II. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
8. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993;14:137-41.
9. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
10. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H. BM 21 0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11.
11. Monier-Faugere M-C, Friedler RM, Bauss F, Malluche HH. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993;8:1345-55.
12. Wüster C, Schöter KH, Thiébaud D, Manegold C, Krahl D, Clemens MR, Ghielmini M, Jaeger P, Scharla SH. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphophonate for the treatment of cancer associated with hypercalcemia Bone Miner 1993;22:77-85.
13. Aubert JP, Milhaud G. Méthode de mesure des principales voies du métabolisme du calcium chez l'homme. Biochim Biophys Acta 1960;39.122-39.
14. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ. The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 1972;48:157-60.
15. Morgan DB, Gasser A, Largiadèr U, Jung A, Fleisch H. Effects of a diphosphonate on calcium metabolism in calcium-deprived rats. Am J Physiol 1975;226:1750-6.
16. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1683-700.
17. 2D in response to inhibition of bone resorption. Am J Physiol 1988;254:E260-4.
18. Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, Vignon E, Mathieu L, Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979;2:489-92.
19. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Danis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993;67:560-3.
20. Thiébaud D, Jaeger P, Gobelet C, Jacquet AF. Single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 1988;85:207-12.